Diakonos Oncology's DOC1021 Clears First Safety Review in Phase 2 Glioblastoma Trial
核心洞察
Independent Data Safety Monitoring Board recommends continuation of Phase 2 DOC-GBM2 trial without modification after finding no safety concerns in the first six months of treatment.
DOC1021 is a first-in-class patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA to target the complete cancer antigen pool.
The therapy's safety profile in the Phase 2 study remains consistent with prior Phase 1 data, providing confidence for continued development in newly diagnosed glioblastoma (搜索) patients.
Diakonos Oncology (搜索) announced that the independent Data Safety Monitoring Board (DSMB) overseeing its Phase 2 DOC-GBM2 clinical trial has completed a scheduled safety review and recommended that the study continue as planned without modification. The review, conducted approximately six months after the first patient was treated, found no safety concerns with DOC1021 in patients with newly diagnosed glioblastoma (搜索) (GBM).
Safety Profile Consistent with Earlier Data
The DSMB's recommendation followed a comprehensive review of available safety data from patients randomized in the DOC-GBM2 study. According to Laura Aguilar, M.D., Ph.D., Chief Medical Officer at Diakonos Oncology (搜索), the safety profile for DOC1021 in this study remains consistent with prior Phase 1 data.
"Ensuring patient safety remains central to our clinical development efforts, particularly in serious and hard-to-treat cancers such as glioblastoma (搜索)," Aguilar stated. "It is reassuring to see a safety profile for DOC1021 in this study that is consistent with prior Phase 1 data, and the independent committee's recommendation to continue this Phase 2 trial without modification provides added confidence as we progress the development of DOC1021 for patients with glioblastoma."
Novel Double-Loading Approach
DOC1021 represents a first-in-class, patient-derived double-loaded dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is manufactured using a patient's dendritic cells (搜索) combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.
The unique double-loading approach mimics a viral infection, unlocking a synergistic and exponentially more powerful tumor killing TH1 response (搜索) driven by dual protein and RNA antigen sourcing. This mechanism allows targeting of the complete cancer antigen pool without requiring molecular modification of the patient's immune cells for manufacturing.
Streamlined Administration
Unlike other immunotherapies, DOC1021 does not require preconditioning chemotherapy or high dose IL-2 for administration. The therapy allows for simple administration in the outpatient setting and broad reach via community cancer centers, potentially expanding access to patients who might not otherwise receive advanced immunotherapy treatments.
Expanding Clinical Pipeline
Diakonos currently operates two active clinical trials with DOC1021: the Phase 1 pancreatic cancer (搜索) study (NCT04157127) and the Phase 2 glioblastoma (搜索) study (NCT06805305). The company has received Fast Track designations from the FDA for both the GBM and pancreatic cancer programs, granted in October 2023 and May 2024, respectively. Additionally, Diakonos received Orphan Drug Designation for the GBM program in January 2024.
A refractory melanoma (搜索) Phase 1/2 study with DOC1021 (NCT07288112) will be initiated early this year with facilitation and support from the Cancer Prevention and Research Institute of Texas (搜索) (CPRIT), further expanding the therapeutic's potential applications across multiple aggressive cancer types.